The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Top myeloma highlights from ASH 2024 & trials to look out for in 2025: expert insights
In this exclusive video compilation, hear directly from leading experts as they share their top highlights in multiple myeloma from the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. This roundup features:
• Rahul Banerjee and Karthik Ramasamy, who discuss exciting findings from the AQUILA trial (NCT03301220), which demonstrated a benefit in patients with high-risk smoldering multiple myeloma (SMM) treated with daratumumab monotherapy versus active observation;
• Ola Landgren, who highlights novel approaches for newly diagnosed myeloma, the value of measurable residual disease (MRD) detection, and early drug development;
• Alexander Lesokhin, who highlights novel induction approaches being explored with bispecific antibody-based combinations.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
